Aldeyra Therapeutics Statistics
Total Valuation
ALDX has a market cap or net worth of $130.76 million. The enterprise value is $44.91 million.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ALDX has 59.71 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 59.71M |
| Shares Outstanding | 59.71M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 2.58% |
| Owned by Institutions (%) | 39.17% |
| Float | 47.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.59, with a Debt / Equity ratio of 0.22.
| Current Ratio | 5.59 |
| Quick Ratio | 5.44 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.21 |
Financial Efficiency
Return on equity (ROE) is -58.54% and return on invested capital (ROIC) is -33.89%.
| Return on Equity (ROE) | -58.54% |
| Return on Assets (ROA) | -29.71% |
| Return on Invested Capital (ROIC) | -33.89% |
| Return on Capital Employed (ROCE) | -69.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$6.21M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.54% in the last 52 weeks. The beta is 0.93, so ALDX's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -43.54% |
| 50-Day Moving Average | 5.39 |
| 200-Day Moving Average | 5.08 |
| Relative Strength Index (RSI) | 29.45 |
| Average Volume (20 Days) | 3,497,702 |
Short Selling Information
The latest short interest is 3.55 million, so 5.94% of the outstanding shares have been sold short.
| Short Interest | 3.55M |
| Short Previous Month | 3.99M |
| Short % of Shares Out | 5.94% |
| Short % of Float | 7.42% |
| Short Ratio (days to cover) | 3.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -60.12M |
| Pretax Income | n/a |
| Net Income | -55.85M |
| EBITDA | -59.87M |
| EBIT | -60.12M |
| Earnings Per Share (EPS) | -$0.94 |
Full Income StatementBalance Sheet
The company has $101.15 million in cash and $15.30 million in debt, giving a net cash position of $85.85 million or $1.44 per share.
| Cash & Cash Equivalents | 101.15M |
| Total Debt | 15.30M |
| Net Cash | 85.85M |
| Net Cash Per Share | $1.44 |
| Equity (Book Value) | 71.00M |
| Book Value Per Share | 1.19 |
| Working Capital | 85.47M |
Full Balance SheetCash Flow
| Operating Cash Flow | -43.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | -43.21M |
| FCF Per Share | -$0.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |